X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

FDA Grants Novartis Cell Therapy For Follicular Lymphoma

Content Team by Content Team
1st June 2022
in FDA Approvals, News

The US Food and Drug Administration (FDA) has granted Novartis expedited approval for its CAR-T cell therapy Kymriah (tisagenlecleucel) to treat people with relapsed or refractory (r/r) follicular lymphoma (FL) following two or more lines of conventional therapy.

As part of the Accelerated Approval Program, continued approval for the existing indication may be contingent on the confirmatory trial (s) demonstrating and explaining clinical benefits. Kymriah can be administered in an outpatient program, giving patients and caregivers more freedom and perhaps lowering the treatment burden.

Kymriah is now licenced for 3 indications and is the only CAR-T cell treatment that has received approval in both adult and paediatric settings. Kymriah was approved by the FDA based on the results of a 90-person, solitary, open-label Phase II ELARA clinical trial.

With a median follow-up of approximately 17 months, the trial evaluated Kymriah’s efficacy. According to the findings, 86% of those who had the Kymriah treatment had a reaction, with 68% having a full response. Kymriah’s safety profile was found to be extraordinary among the 97 participants who were evaluated for safety after a median follow-up of 21 months. There were 53% of participants in the study who had any-grade cytokine release syndrome (CRS) as described by the Lee scale, without any cases of high-grade CRS.

They are proud of the regulatory approval of a third application for Kymriah, said Victor Bulto, head of Novartis Innovative Medicines in the United States. They believe that this therapy strategy, which has the potential for long-term results, will assist patients with follicular lymphoma and also break the relentless cycle of treatment.

The latest breakthrough comes after Kymriah was approved by the European Commission to manage patients with r/r FL.

Previous Post

NRG Earns £2.68m Grant Boost For Neurodegenerative Illness

Next Post

Sandoz Initiates New Worldwide Health Inequality Movement

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Drug Development

Global Biopharma Market to Hit $566B by 2032

7th March 2025
Next Post
Sandoz Initiates New Worldwide Health Inequality Movement

Sandoz Initiates New Worldwide Health Inequality Movement

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In